Biogen, Eisai’s Leqembi wins UK approval, but not immediate NHS coverage

Biogen and Eisai’s Leqembi has been authorized by the UK’s Medicines and Healthcare products Regulatory Agency for Alzheimer’s disease, but a negative opinion from the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Ginkgo Bioworks lays off 158 employees, with more to come

BOSTON — Ginkgo Bioworks, the once-high-flying Boston life sciences firm, on Thursday said it has notified 158 employees that they will be laid off and

June 21, 2024

European regulators tout their accomplishments against pharma’s anticompetitive practices

European antitrust regulators want you to know that fighting crime in the pharmaceutical industry pays. Between 2018 and 2022, the European Commission and antitrust regulators

January 29, 2024

Illumina cut 12% of global staff over past year: CEO

By the numbers Q4 Revenue: $1.12 billion Up 3.6% year over year Q4 Net loss: $176 million Compared with a net loss of $140 million

February 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.